CHESTER SPRINGS, PA — Curadh MTR Inc. and Alpha Fusion, Inc. are set to showcase advances in cancer treatment using Astatine-211 (At-211) radiopharmaceuticals at the upcoming 4th Targeted Radiopharmaceuticals Summit US in San Diego. The companies are deepening their collaboration with a new joint venture aimed at accelerating global development of At-211-based therapies for a range of cancers.
The partnership brings together Curadh’s radiopharmaceutical development experience and Alpha Fusion’s early-stage clinical leadership in At-211 therapeutics. Alpha Fusion is currently the only company with multiple At-211-based agents in clinical trials.
Dr. Alison Armour, Curadh’s Chief Medical Officer and founder, will lead a session titled Optimizing Clinical Design to Ensure Patient Safety in Radiopharmaceutical Development. Armour, who recently addressed the World Astatine Community Meeting, emphasized At-211’s short half-life of 7.2 hours as a clinical advantage, noting its potential to reduce radiation exposure for patients and healthcare workers.
“At the recent World Astatine Community Meeting, I presented ‘Why Astatine Will Be Important for The Future of Molecularly Targeted Radiopharmaceuticals,’” said Armour. “Astatine’s short 7.2-hour half-life offers unique benefits over other radioisotopes including significantly reduced radiation exposure to patients, caregivers and healthcare facilities personnel.”
Glenn Kazo, CEO of Curadh, praised Alpha Fusion’s clinical leadership, adding, “Alpha Fusion is currently the only company in the world with multiple At-211-based therapeutics in clinical trials, and we are excited to advance our collaboration based on the outstanding work by Dr. Watabe and the team at Alpha Fusion in Japan.”
Early clinical results are encouraging. At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting, Dr. Tadashi Watabe of the University of Osaka presented data from a Phase I investigator-initiated trial, which demonstrated tolerability and early efficacy of At-211 in patients with thyroid cancer resistant to standard radioiodine therapy.
“With the swift advancements in At-211 clinical development, we are excited to accelerate our expansion into the U.S. and global markets,” said Sunao Fujioka, CEO of Alpha Fusion. “This progress is made possible through our partnership, which combines Alpha Fusion’s platform with Curadh’s extensive expertise in radiopharmaceuticals.”
The joint effort aims to position At-211 as a next-generation option in targeted cancer care, combining precision delivery with safer radiation profiles.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.